Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | Zendy

Jennifer K. Litton | Zendy; Hope S. Rugo | Zendy; Johannes Ettl | Zendy; Sara A. Hurvitz | Zendy; Anthony Gonçalvès | Zendy; Kyung-Hun Lee | Zendy; Louis Fehrenbacher | Zendy; Rinat Yerushalmi | Zendy; Lida A. Mina | Zendy; Miguel Martín | Zendy; Henri Roché | Zendy; YoungHyuck Im | Zendy; Ruben G.W. Quek | Zendy; Denka Markova | Zendy; Iulia Cristina Tudor | Zendy; Alison L. Hannah | Zendy; W. Eiermann | Zendy; Joanne L. Blum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Author(s) -

Jennifer K. Litton,

Hope S. Rugo,

Johannes Ettl,

Sara A. Hurvitz,

Anthony Gonçalvès,

Kyung-Hun Lee,

Louis Fehrenbacher,

Rinat Yerushalmi,

Lida A. Mina,

Miguel Martín,

Henri Roché,

YoungHyuck Im,

Ruben G.W. Quek,

Denka Markova,

Iulia Cristina Tudor,

Alison L. Hannah,

W. Eiermann,

Joanne L. Blum

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1802905

Subject(s) - medicine , hazard ratio , eribulin , vinorelbine , breast cancer , oncology , adverse effect , odds ratio , metastatic breast cancer , surgery , confidence interval , cancer , chemotherapy , cisplatin

The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research